Giovanni Di Zenzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/529483/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science, 2016, 353, 179-184.	12.6	468
2	Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clinical Immunology, 2008, 128, 415-426.	3.2	173
3	Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface. Journal of Clinical Investigation, 2012, 122, 3781-3790.	8.2	142
4	Demonstration of Epitope-Spreading Phenomena in Bullous Pemphigoid: Results of a Prospective Multicenter Study. Journal of Investigative Dermatology, 2011, 131, 2271-2280.	0.7	132
5	Bullous pemphigoid: From the clinic to the bench. Clinics in Dermatology, 2012, 30, 3-16.	1.6	123
6	Bullous Pemphigoid: Physiopathology, Clinical Features and Management. Advances in Dermatology, 2007, 23, 257-288.	2.0	101
7	New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update. Frontiers in Immunology, 2019, 10, 1506.	4.8	99
8	Characterization of the Anti-BP180 Autoantibody Reactivity Profile and Epitope Mapping in Bullous Pemphigoid Patients11Tables 1, 2, 3 and 5 can be found at http://www.blackwellpublishing.com/products/journals/suppmat/jid/jid22126/jid22126sm.htm. Journal of Investigative Dermatology, 2004, 122, 103-110.	0.7	89
9	Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-β signalling in modifying disease severity. Human Molecular Genetics, 2014, 23, 3907-3922.	2.9	88
10	European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1926-1948.	2.4	86
11	Bullous Pemphigoid: Trigger and Predisposing Factors. Biomolecules, 2020, 10, 1432.	4.0	81
12	Humoral Epitope Spreading in Autoimmune Bullous Diseases. Frontiers in Immunology, 2018, 9, 779.	4.8	77
13	Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients. British Journal of Dermatology, 2004, 151, 1004-1010.	1.5	75
14	European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1750-1764.	2.4	72
15	Immune response in pemphigus and beyond: progresses and emerging concepts. Seminars in Immunopathology, 2016, 38, 57-74.	6.1	68
16	Oral lichenoid tissue reactions: diagnosis and classification. Expert Review of Molecular Diagnostics, 2014, 14, 169-184.	3.1	63
17	The Intracellular and Extracellular Domains of BP180 Antigen Comprise Novel Epitopes Targeted by Pemphigoid Gestationis Autoantibodies. Journal of Investigative Dermatology, 2007, 127, 864-873.	0.7	57
18	Oral pemphigoid autoantibodies preferentially target BP180 ectodomain. Clinical Immunology, 2007, 122, 207-213.	3.2	51

#	Article	IF	CITATIONS
19	Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseases. Journal of the American Academy of Dermatology, 2017, 76, 889-894.e5.	1.2	46
20	Determining the Incidence of <i>Pneumocystis</i> Pneumonia in Patients With Autoimmune Blistering Diseases Not Receiving Routine Prophylaxis. JAMA Dermatology, 2017, 153, 1137.	4.1	43
21	Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. Journal of the American Academy of Dermatology, 2018, 78, 592-595.	1.2	39
22	Mammalian cell transduction and internalization properties of λ phages displaying the full-length adenoviral penton base or its central domain. Journal of Molecular Medicine, 2004, 82, 467-476.	3.9	38
23	Urban legend series: mucous membrane pemphigoid. Oral Diseases, 2014, 20, 35-54.	3.0	38
24	Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016. Journal of Investigative Dermatology, 2017, 137, 1199-1203.	0.7	34
25	Immunoglobulin E and bullous pemphigoid. European Journal of Dermatology, 2018, 28, 440-448.	0.6	34
26	Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases. BMC Immunology, 2012, 13, 16.	2.2	30
27	Serological diagnostics in the detection of IgG autoantibodies against human collagen VII in epidermolysis bullosa acquisita: a multicentre analysis. British Journal of Dermatology, 2017, 177, 1683-1692.	1.5	30
28	Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study. Frontiers in Medicine, 2022, 9, 841506.	2.6	30
29	Sequential Intramolecular Epitope Spreading of Humoral Responses to Human BPAG2 in a Transgenic Model. Journal of Investigative Dermatology, 2010, 130, 1040-1047.	0.7	28
30	Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology. Journal of the American Academy of Dermatology, 2020, 83, 1315-1322.	1.2	28
31	Contribution of the different modules in the utrophin carboxy-terminal region to the formation and regulation of the DAP complex. FEBS Letters, 2000, 471, 229-234.	2.8	26
32	Anti-desmoplakin antibodies in erythema multiforme and Stevens-Johnson syndrome sera: pathogenic or epiphenomenon?. European Journal of Dermatology, 2011, 21, 32-36.	0.6	25
33	Detection of IgG and IgE reactivity to BP180 using the ISAC®microarray system. British Journal of Dermatology, 2013, 168, 1205-1214.	1.5	24
34	IgE autoantibodies in serum and skin of nonâ€bullous and bullous pemphigoid patients. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 973-980.	2.4	22
35	Autoantibody Profile of a Cohort of 78 Italian Patients with Mucous Membrane Pemphigoid: Correlation Between Reactivity Profile and Clinical Involvement. Acta Dermato-Venereologica, 2014, 96, 768-73.	1.3	21
36	Are clinical phenotype and autoantibody profile always concordant in pemphigus? A study in a cohort of pemphigus patients. European Journal of Dermatology, 2013, 23, 40-48.	0.6	20

GIOVANNI DI ZENZO

#	Article	IF	CITATIONS
37	Induction of senescence pathways in Kindler syndrome primary keratinocytes. British Journal of Dermatology, 2013, 168, 1019-1026.	1.5	18
38	Increased prevalence of diabetes mellitus in bullous pemphigoid patients during the last decade. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e153-e154.	2.4	17
39	Evaluation of cutaneous, oral and intestinal microbiota in patients affected by pemphigus and bullous pemphigoid: A pilot study. Experimental and Molecular Pathology, 2020, 112, 104331.	2.1	16
40	Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin. Journal of Translational Medicine, 2021, 19, 520.	4.4	15
41	Sensitivity of different assays for the serological diagnosis of epidermolysis bullosa acquisita: analysis of a cohort of 24 Italian patients. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 483-490.	2.4	12
42	Endemic Pemphigus Foliaceus: Towards Understanding Autoimmune Mechanisms of Disease Development. Journal of Investigative Dermatology, 2012, 132, 2499-2502.	0.7	11
43	A truncating mutation in the laminin-332α chain highlights the role of the LG45 proteolytic domain in regulating keratinocyte adhesion and migration. British Journal of Dermatology, 2014, 170, 1056-1064.	1.5	11
44	Childhood epidermolysis bullosa acquisita during squaric acid dibutyl ester immunotherapy for alopecia areata. British Journal of Dermatology, 2017, 176, 491-494.	1.5	11
45	Epidermolysis Bullosa (EB) Acquisita in an Adult Patient with Previously Unrecognized Mild Dystrophic EB and Biallelic COL7A1 Mutations. Acta Dermato-Venereologica, 2018, 98, 411-415.	1.3	11
46	Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study. Journal of the American Academy of Dermatology, 2022, 87, 56-63.	1.2	10
47	Interâ€rater reliability of the BIOCHIP indirect immunofluorescence dermatology mosaic in bullous pemphigoid and pemphigus patients. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2327-2333.	2.4	9
48	Pemphigus Vulgaris: Present and Future Therapeutic Strategies. Dermatology Practical and Conceptual, 2022, 12, e2022037.	0.9	9
49	Paraneoplastic Pemphigus Presenting as Mild Cutaneous Features of Pemphigus Foliaceus and Lichenoid Stomatitis with Antidesmoglein 1 Antibodies. Dermatology Research and Practice, 2010, 2010, 1-5.	0.8	8
50	Commentary on â€~Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidaseâ€4 inhibitors'. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e439-e440.	2.4	8
51	The pathogenic activity of anti-desmoglein autoantibodies parallels disease severity in rituximab-treated patients with pemphigus vulgaris. European Journal of Dermatology, 2015, 25, 578-585.	0.6	7
52	The pathogenesis of pemphigus: Controversy vs complexity. Experimental Dermatology, 2017, 26, 1271-1273.	2.9	7
53	Lack of K140 immunoreactivity in junctional epidermolysis bullosa skin and keratinocytes associates with misfolded laminin epidermal growth factor-like motif 2 of the β3 short arm. British Journal of Dermatology, 2018, 178, 1416-1422.	1.5	7
54	Minocycline in combination with mycophenolate mofetil in oral mucous membrane pemphigoid. European Journal of Dermatology, 2008, 18, 198-200.	0.6	7

GIOVANNI DI ZENZO

#	Article	IF	CITATIONS
55	A compound synonymous mutation c.474G>A with p.Arg578X mutation in <i><scp>SPINK</scp>5</i> causes splicing disorder and mild phenotype in Netherton syndrome. Experimental Dermatology, 2016, 25, 568-570.	2.9	6
56	Paraneoplastic autoimmune multiorgan syndrome. Italian Journal of Dermatology and Venereology, 2021, 156, .	0.2	6
57	A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy. Antibodies, 2021, 10, 19.	2.5	6
58	IgA tracheobronchial deposits underlie respiratory compromise in neonatal linear IgA bullous dermatosis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e333-e335.	2.4	5
59	Paraneoplastic Autoimmune Multi-organ Syndrome: Association with Retroperitoneal Kaposi's Sarcoma. Acta Dermato-Venereologica, 2016, 96, 261-262.	1.3	4
60	Identification of a Novel Non-desmoglein Autoantigen in Pemphigus Vulgaris. Frontiers in Immunology, 2019, 10, 1391.	4.8	4
61	Development of bullous pemphigoid in junctional epidermolysis bullosa. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e146-e148.	2.4	4
62	Sensitivity of Immunofluorescence Studies vs Enzyme-Linked Immunosorbent Assay for Diagnosis of Bullous Pemphigoid. Archives of Dermatology, 2011, 147, 1454.	1.4	3
63	Clonal Analysis of B-Cell Response in Pemphigus Course: Toward More Effective Therapies. Journal of Investigative Dermatology, 2015, 135, 651-654.	0.7	3
64	Pemphigoid Gestationis Complicating an Egg Donation Pregnancy. Acta Dermato-Venereologica, 2016, 96, 695-696.	1.3	3
65	Paraneoplastic Epidermolysis Bullosa Acquisita Associated with Thyroid Carcinoma. Acta Dermato-Venereologica, 2016, 96, 414-415.	1.3	3
66	Bullous pemphigoid with hyperkeratosis and palmoplantar keratoderma: Three cases. Journal of Dermatology, 2018, 45, 1135-1140.	1.2	3
67	May Bacterial Infections Trigger Bullous Pemphigoid? Case Report and Review of Literature. Microorganisms, 2021, 9, 1235.	3.6	3
68	New versatile monoclonal antibodies against type <scp>XVII</scp> collagen endodomain for diagnosis and subtyping <i><scp>COL</scp>17A1</i> â€associated junctional epidermolysis bullosa. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1426-1427.	2.4	1
69	Blistering lesions associated with Waldenström macroglobulinemia: New insights into pathogenesis. Dermatologic Therapy, 2021, 34, e15072	1.7	1
70	Bullous Pemphigoid: Clinical Features, Diagnostic Markers, and Immunopathogenic Mechanisms. , 2011, , 65-95.		1